CDK9 and glioblastoma: PHA-767491, a selective ATP-competitive dual inhibitor cdc7/CDK9, was described to enhance replicative stress, apoptosis, and radiosensitivity in GBM via suppression of RAD54L in vitro and in vivo [64] (Fig. 5).